Krystal Biotech Shares Drop Following Delay in Pipeline Data Releases
Krystal Biotech (KRYS) shares fell approximately 13% during Monday morning trading despite the company reporting third-quarter financial results that exceeded analyst expectations for both revenue and earnings. The stock decline was triggered by an announcement that data releases for several key pipeline candidates, which investors had anticipated by the end of this year, have been pushed back to 2027. This significant delay in clinical milestones has dampened investor sentiment regarding the company's near-term growth catalysts.
Tickers: $KRYS